Evaluation of serum procathepsin B, cystatin B and cystatin C as possible biomarkers of ovarian cancer

References

• Gupta D, Lammersfeld L, Vashi PG, Dahik S, Grutsch JF, Lis CG. Is serum albumin an independent predictor of survival in ovarian cancer?. Clinical Ovarian Cancer. 2009; 2: 52–6.
   Google Scholar
• Liliac L, Amalinei C, Balan R, Grigoras A, Caruntu ID. Ovarian cancer: insights into genetics and pathogeny. Histol Histopathol. 2012; 27: 707–19.
   Web of Science ®Google Scholar
• Kolwijck E, Kos J, Obermajer N, Span PN, Thomas CM, Massuger LF, etal. The balance between extracellular cathepsins and cystatin C is of importance for ovarian cancer. Eur J Clin Invest. 2010; 40: 591–9.
   PubMed Web of Science ®Google Scholar
• Kolwijck E, Massuger LF, Thomas CM, Span PN, Krasovec M, Kos J, etal. Cathepsins B, L and cystatin C in cyst fluid of ovarian tumors. J Cancer Res Clin Oncol. 2010; 136: 771–8.
   PubMed Web of Science ®Google Scholar
• Turk V, Bode W. The cystatins: protein inhibitors of cysteine proteinases. FEBS Lett. 1991; 285: 213–9.
   PubMed Web of Science ®Google Scholar
• Kos J, Lah TT. Cysteine proteinases and their endogenous inhibitors: target proteins for prognosis, diagnosis and therapy in cancer (review). Oncol Rep. 1998; 5: 1349–61.
   PubMed Web of Science ®Google Scholar
• Lah TT, Kokalj-Kunovar M, Kastelic L, Babnik J, Stolfa A, Rainer S, etal. Cystatins and stefins in ascites fluid from ovarian carcinoma. Cancer Lett. 1992; 61: 243–53.
   PubMed Web of Science ®Google Scholar
• Caglic D, Pungercar JR, Pejler G, Turk V, Turk B. Glycosaminoglycans facilitate procathepsin B activation through disruption of propeptide–mature enzyme interactions. J Biol Chem. 2007; 282: 33076–85.
   PubMed Web of Science ®Google Scholar
• Pungercar JR, Caglic D, Sajid M, Dolinar M, Vasiljeva O, Pozgan U, etal. Autocatalytic processing of procathepsin B is triggered by proenzyme activity. FEBS J. 2009; 276: 660–8.
   PubMed Web of Science ®Google Scholar
• Mulaomerović A, Halilbasić A, Cickusić E, Zavasnik-Bergant T, Begić L, Kos J. Cystatin C as a potential marker for relapse in patients with non-Hodgkin B-cell lymphoma. Cancer Lett. 2007; 248: 192–7.
   Web of Science ®Google Scholar
• Bespalova IN, Adkins S, Pranzatelli M, Burmeister M. Novel cystatin B mutation and diagnostic PCR assay in an Unverricht-Lundborg progressive myoclonus epilepsy patient. Am J Med Genet. 1997; 74: 467–71.
   PubMed Web of Science ®Google Scholar
• Kastelic L, Turk B, Kopitar-Jerala N, Stolfa A, Rainer S, Turk V, etal. Stefin B, the major low molecular weight inhibitor in ovarian carcinoma. Cancer Lett. 1994; 82: 81–8.
   Web of Science ®Google Scholar
• Kos J, Krasovec M, Cimerman N, Nielsen H, Christensen IJ, Brunner N. Cysteine protease inhibitor stefin A, stefin B, and cystatin C in sera from patients with colorectal cancer; relation to prognosis. Clin Cancer Res. 2000; 6: 505–11.
   PubMed Web of Science ®Google Scholar
• Keppler D. Towards novel anti-cancer strategies based on cystatin function. Cancer Lett. 2006; 235: 159–76.
   PubMed Web of Science ®Google Scholar
• Warwas M, Haczynska H, Gerber J, Nowak M. Cathepsin B-like activity as a serum tumour marker in ovarian carcinoma. Eur J Clin Chem Clin Biochem. 1997; 35: 301–4.
   PubMedGoogle Scholar
• Carmignani CP, Sugarbaker TA, Bromley CM, Sugarbaker PH. Intraperitoneal cancer dissemination: mechanisms of the patterns of spread. Cancer Metastasis Rev. 2003; 22: 465–72.
   PubMedGoogle Scholar
• Nishikawa H, Ozaki Y, Nakanishi T, Blomgren K, Tada T, Arakawa A, etal. The role of cathepsin B and cystatin C in the mechanisms of invasion by ovarian cancer. Gynecol Oncol. 2004; 92: 881–6.
   PubMed Web of Science ®Google Scholar
• Terpos E, Katodritou E, Tsiftsakis E, Kastritis E, Christoulas D, Pouli A, etal. Cystatin C is an independent prognostic factor for survival in multiple myeloma and is reduced by bortezomib administrayion. Haematologica. 2009; 94: 372–9.
   PubMed Web of Science ®Google Scholar
• Mai J, Finley RL Jr , Waisman DM, Sloane BF. Human procathepsin B interacts with the annexin II tetramer on the surface of tumor cells. J Biol Chem. 2000; 275: 12806–12.
   PubMed Web of Science ®Google Scholar
• Cavallo-Medved D, Mai J, Dosescu J, Sameni M, Sloane BF. Caveolin-1 mediates the expression and localization of cathepsin B, pro-urokinase plasminogen activator and their cell-surface receptor in human colorectal carcinoma cells. J Cell Sci. 2005; 118(Pt 7): 1493–503.
   PubMed Web of Science ®Google Scholar
• Roshy S, Sloane BF, Moin K. Pericellular cathepsin B and malignant progression. Cancer Metastasis Rev. 2003; 22: 271–86.
   PubMed Web of Science ®Google Scholar
• Barbarin A, Frade R. Procathepsin L secretion, which triggers tumour progression, is regulated by Rab4a in human melanoma cells. Biochem J. 2011; 437: 97–107.
   Web of Science ®Google Scholar
• Decock J, Obermajer N, Vozelj S, Hendrickx W, Paridaens R, Kos J. Cathepsin H, catepsin X and cystatin C in sera of patients with early-stage and inflammatory breast cancer. Int J Biol Markers. 2008; 23: 1–7.
   Web of Science ®Google Scholar
• Bodnar L, Wcislo GB, Smoter M, Gasowska-Bodnar A, Stec R, Synowiec A, etal. Cystatin C as a parameter of glomerular filtration rate in patients with ovarian cancer. Kidney Blood Press Res. 2010; 33: 360–7.
   PubMed Web of Science ®Google Scholar
• Korolenko TA, Filatova TG, Cherkanova MS, Khalikova TA, Bravve IIu. Cystatins: cysteine proteases regulation and disturbances in tumors and inflammation. Biomed Khim. 2008; 54: 210–7.
   Google Scholar
• Korolenko TA, Cherkanova MS, Gashenko EA, Johnston TP, Bravve IYu. Cohen J, Ryseck LP. Cystatin C, atherosclerosis and lipid-lowering therapy by statins. Cystatins, protease inhibitors. 2011; New York: Nova Science Publisher. 187–204.
   Google Scholar